Dr. Haydn Pritchard served as Program Director – Graduate Studies for the Department from July 1st, 2009 to July 2014. Dr Pritchard has been with our Department for over 25 years after coming to UBC from England in 1978 as a Killam Fellow in Biochemistry. He received a BC Health Care Research Foundation Scholarship and established his laboratory in Pathology within the clinical units of the Lipid Clinic at the old Shaughnessy Hospital and subsequently in the Healthy Heart Program of St Paul’s Hospital. Together with fellow Department member, Dr Jiri Frohlich, they established their research program in the area of genetic and environmental factors that control cholesterol metabolism. Their work rapidly established them as national and international opinion leaders in the discipline of lipoprotein metabolism. This blend of clinical and basic science lead Dr Pritchard to significant collaborations with the biotechnology industry.
He is a co-inventor of VisuDyne from Quadralogics, and served as a Senior Vice President for Pharmaceutical Research at Forbes MediTech Inc. Dr Pritchard was promoted to full professor 1993. In 2001, Dr. Pritchard turned his attention to the health promotion needs of patients at risk for cardiovascular disease and co-founded the Healthy Heart Society of BC, again with Jiri Frohlich. This organization focuses on health care providers across the province to assist them in addressing and developing strategies for the primary and secondary prevention of cardiovascular disease. More recently, he has founded a new organization, IMPACT BC, whose mandate is to deliver the quality improvement strategies of the BC Ministry of Health and BCMA with respect to primary care providers. These organizations have currently raised over $20 million from governmental and corporate supporters. Outside of research, business and health promotion, Dr Pritchard has significant experience with not for profit societies. He has served as a Vice President for the Mountain Equipment Cooperative and has also played leadership roles in coaching and administration for several local youth and senior soccer clubs. He remains an active mountaineer and ocean kayaker.
In taking up his appointment, Dr Pritchard indicated that he is delighted to be given the opportunity but recognizes how hard it will be to follow in the footsteps of Dr. David Walker who served in this role for the past 7 years. Dr Pritchard stated that he is looking forward to working with the students and faculty alike to maintain and further develop a learning environment of choice that capitalizes on individual student strengths and provides a safe, tolerant and supportive environment that helps each student overcome challenges. Dr Pritchard will establish his office at UBC and he can be reached at: firstname.lastname@example.org and (604) 551-2773. A good way to track him down is on Skype: haydnpritchard.
- PhD, University of Nottingham, U.K., Biochemistry. 1978
- BSc (Hons), Trent Polytechnic, Nottingham, U.K., Applied Biology. 1975
- Wasan KM, Goss PE, Pritchard PH, Sheperd L Tu D, Ingle JN Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC GTC MA. 17 sub study Breast Cancer Research 2012 136(3) 769-76.
- Murray KR, Nair MP, Ayyobi AF, Hill JS, Pritchard PH, Lacko AG. 2001. Probing the 121-136 domain of lecithin: cholesterol acyltransferase using antibodies. Archives of Biochemistry and Biophysics 385:267-275.
- Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. 1997. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. Journal of Lipid Research 38:191-205.
- Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard PH, Frohlich J, Clerk M, Dumon M-F, Fairwell T, Zech L, Santanmarina-Fojo S, and Brewer HB, Jr. Markedly accelerated catabolism of apolipoprotein AII (ApoAII) and high density lipoproteins containing ApoAI in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest. (1994).
- Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP, Jr, Pritchard PH, Frohlich J, Lees RS, Bernard GF, Ordovas JM and Schaefer EJ. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis (1994).
- Cardiovascular & Pulmonary